VivoSeq
Other

Atopic

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Atopic is an early-stage landscape with 0 programs across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Completed3 · 100%

Clinical Trials

Trial Activity

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects
Completed·—·N/A·NCT03039101·25 enrolled
Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease
Completed·UUniversity Hospital Muenster·Phase 2·NCT00507832·30 enrolled
Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects
Completed·Novartis logoNovartis·Phase 1·NCT00620230·46 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)